1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,482 | 0,530 | 12:42 | |
| 0,482 | 0,530 | 12:42 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| OCUMENSION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Di | OCUMENSION-B OT-101 Eye Drops Meet Primary Endpoint in Phase III Trial for Myopia Progression Delay | 1 | AASTOCKS | ||
| Di | OCUMENSION-B (01477): INSIDE INFORMATION ANNOUNCEMENT TOPLINE RESULTS OF THE MONTH 36 PRIMARY ANALYSIS OF THE GLOBAL MULTI-CENTRE PHASE III CLINICAL TRIAL ... | 5 | HKEx | ||
| 24.09. | OCUMENSION-B (01477): 2026 INTERIM REPORT | 1 | HKEx | ||
| 11.09. | OCUMENSION-B (01477): VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION OF OT-301 ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION | 2 | HKEx | ||
| 02.09. | OCUMENSION-B (01477): VOLUNTARY ANNOUNCEMENT PATIENT ENROLLMENT COMPLETED IN THE PHASE III CLINICAL TRIAL OF OT-211 | - | HKEx | ||
| 01.09. | OCUMENSION-B (01477): VOLUNTARY ANNOUNCEMENT ACCEPTANCE OF APPLICATION FOR DRUG REGISTRATION OF DOMESTICALLY PRODUCED DEXAMETHASONE INTRAOCULAR SUSPENSION | - | HKEx | ||
| 31.08. | OCUMENSION-B (01477): VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLMENT COMPLETED IN THE PHASE III CLINICAL TRIAL OF OT-202 | - | HKEx | ||
| 28.08. | OCUMENSION-B (01477): CHANGE IN USE OF PROCEEDS | 1 | HKEx | ||
| 28.08. | OCUMENSION-B (01477): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | - | HKEx | ||
| 14.08. | OCUMENSION-B (01477): DATE OF BOARD MEETING | - | HKEx | ||
| 10.08. | NICOX SA: Nicox Announces NCX 470 NDA Submission in China by Partner Ocumension | 715 | GlobeNewswire (Europe) | Press Release Nicox Announces NCX 470 NDA Submission in China by Partner Ocumension
Ocumension has submitted the New Drug Application (NDA) to the Chinese National Medical Products Administration... ► Artikel lesen | |
| 02.07. | OCUMENSION-B (01477): VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION OF OT-502 APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION | 1 | HKEx | ||
| 30.06. | OCUMENSION-B (01477): RESIGNATION OF CHIEF FINANCIAL OFFICER AND JOINT COMPANY SECRETARY AND CHANGE IN AUTHORIZED REPRESENTATIVE | 1 | HKEx | ||
| 30.06. | OCUMENSION-B (01477): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION | - | HKEx | ||
| 30.06. | OCUMENSION-B (01477): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 30, 2026 AND APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE ... | - | HKEx | ||
| 08.06. | OCUMENSION-B (01477): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON TUESDAY, JUNE 30, 2026 | 1 | HKEx | ||
| 08.06. | OCUMENSION-B (01477): NOTICE OF ANNUAL GENERAL MEETING | 2 | HKEx | ||
| 08.06. | OCUMENSION-B (01477): PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; PROPOSED RE-ELECTION OF RETIRING DIRECTORS AND PROPOSED ... | 1 | HKEx | ||
| 28.05. | OCUMENSION-B (01477): VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLMENT COMPLETED IN THE PHASE III CLINICAL TRIAL OF OT-802 | - | HKEx | ||
| 12.05. | OCUMENSION-B (01477): GRANTS OF OPTIONS AND AWARDS | - | HKEx |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 43,930 | -1,57 % | Buy or Goodbye?: Tesla, Totalenergies, Nestle und Bayer - Die Analystenstimmen des Tages | © Foto: Ding Ting/XinHua/dpaTesla, Totalenergies, Nestle und Bayer: Die wichtigsten Analysten-Updates im Überblick Enthaltene Werte: DE000BAY0017,FR0000120271,CH0038863350,US88160R1014Den vollständigen... ► Artikel lesen | |
| NOVO NORDISK | 35,160 | +1,03 % | 500.000 USD Mindestabnahme: Diese Small-Cap-Aktie könnte nach dieser News vor einer spannenden Neubewertung stehen! | ||
| PFIZER | 26,760 | +0,66 % | Community Rückblick: BioNTech BNT113 Studie verfehlt Endpunkt: "Die Bude treibt einen zum Wahnsinn!" | © Foto: Julia Cebella - dpaBioNTech verfehlt mit BNT113 ein wichtiges Studienziel. Im wO-Forum streiten Anleger über die Zukunft der mRNA-Krebsforschung, die Bewertung der Aktie und das Potenzial der... ► Artikel lesen | |
| MERCK KGAA | 144,70 | +1,72 % | Eli Lillys Umsatzsprung, Mercks 11,3-Milliarden-Dollar-Deal: Wie Zelltherapien in die Wachstumsstory der Pharmabranche passen | ||
| GILEAD SCIENCES | 138,82 | +1,54 % | BofA hebt Kursziel für Gilead Sciences nach positiven Studiendaten an | ||
| AURORA CANNABIS | 3,442 | -2,49 % | Curaleaf Holdings, Inc.: Curaleaf Challenges Aurora's Unilateral Rejection of Its Enhanced Proposal | STAMFORD, Conn., Oct. 19, 2026 /CNW/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer... ► Artikel lesen | |
| SANOFI | 73,19 | -0,01 % | UBS stuft SANOFI auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Sanofi vor den am 30. Oktober erwarteten Zahlen auf "Neutral" mit einem Kursziel von 78 Euro belassen. Er rechnet mit einem... ► Artikel lesen | |
| ABBVIE | 255,30 | +0,75 % | Dividendenbekanntmachungen (15.10.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBOTT LABORATORIES US0028241000 0,63 USD 0,5648 EUR ABBOTT LABORATORIES CDR CA0028221046 0,1096 CAD 0,069 EUR ABBVIE INC US00287Y1091 1... ► Artikel lesen | |
| ELI LILLY | 1.145,40 | +1,17 % | If You Invested $100 In Eli Lilly Stock 20 Years Ago, You Would Have This Much Today | ||
| CANOPY GROWTH | 0,596 | -1,13 % | Trump's Marijuana Order Is Stuck at the DEA. Here's What That Means for Canopy Growth. | ||
| MERCK & CO | 134,48 | +0,79 % | Merck's KEYTRUDA Plus Padcev Wins EU Approval For Muscle-Invasive Bladder Cancer | KENILWORTH (NJ) (dpa-AFX) - Merck & Co Inc.(MRK) announced that the European Commission approved KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) as perioperative treatment for... ► Artikel lesen | |
| ASTRAZENECA | 151,15 | +0,80 % | AstraZeneca's Ultomiris Gets FDA Accelerated Approval As First C5 Inhibitor For IgAN | BASEL (dpa-AFX) - The U.S. FDA on Wednesday approved AstraZeneca (AZN) subsidiary Alexion's Ultomiris to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk... ► Artikel lesen | |
| TILRAY BRANDS | 2,625 | +0,77 % | Tilray Brands, Inc.: West Ham United F.C. and BrewDog Unveil Boleyn Brew: A Fan-Created Matchday Beer Made by Hammers, for Hammers | ELLON, Scotland and LONDON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- BrewDog, a leader in U.K. craft beer and one of the world's most recognised beer brands, owned by Tilray Brands, Inc. (NASDAQ: TLRY... ► Artikel lesen | |
| BRISTOL-MYERS SQUIBB | 54,89 | +0,81 % | SONDERMELDUNG: Warum die Aktie von Bristol-Myers Squibb Company von unseren Experten eine 3+ bekommt - Handeln Sie noch vor Börsenschluss! | ||
| TEVA PHARMACEUTICAL INDUSTRIES | 40,590 | -0,06 % | Teva/Sanofi: Duvakitug Maintains Meaningful Efficacy Improvements In Long-term Extension Study | PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), and Sanofi announced new positive data from the RELIEVE UCCD phase 2b long-term extension... ► Artikel lesen |
Das Unternehmen OCUMENSION THERAPEUTICS kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,006 (-1,20 %) liegt der Kurs bei 0,492 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OCUMENSION THERAPEUTICS finden Sie auf Wallstreet Online.